{
    "clinical_study": {
        "@rank": "36663", 
        "acronym": "JIFI", 
        "arm_group": [
            {
                "arm_group_label": "STRATIS", 
                "arm_group_type": "Experimental", 
                "description": "Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device."
            }, 
            {
                "arm_group_label": "Needle-Syringe", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the administration of a seasonal flu vaccine\n      using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and\n      syringe administration, as measured by laboratory tests of immune response."
        }, 
        "brief_title": "Jet Injection for Influenza", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza, Human", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults aged \u226518 and \u226464 years of age at the time of enrollment\n\n          -  Willing and able to give informed consent after reading the consent form and adequate\n             opportunity to discuss the study with the investigator or qualified designee\n\n          -  Willing and able to adhere to all protocol required study procedures and to attend\n             scheduled visits.\n\n          -  Able to receive the TIV influenza vaccine, based on UCH employee health flu screening\n             guidelines.\n\n          -  Stable health status with no exclusionary medical or neuropsychiatric conditions as\n             determined during the screening evaluation and based on the clinical judgment of the\n             investigator or qualified designee.\n\n          -  Access to a consistent means of telephone contact\n\n        Exclusion Criteria:\n\n          -  Presence of any febrile illness (oral temperature >38\u00b0C) on the day of immunization.\n             Such subjects will be reevaluated for enrollment after resolution of illness.\n\n          -  Presence of significant acute or chronic uncontrolled medical or neuropsychiatric\n             illness and /or presence of any significant condition that may prohibit inclusion as\n             determined by the investigator or his qualified designee. Uncontrolled is defined as:\n             requiring institution of a new treatment within 1 month prior to study enrollment or\n             change in medication dosage in the month prior to study enrollment.\n\n          -  Any immunosuppressive condition including: history of HIV infection, cancer or cancer\n             treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose \u226510\n             mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more\n             days in total) within 1 month of study enrollment, or any other cytotoxic or\n             immunosuppressive drug within 3 months of study enrollment. Any significant disorder\n             of coagulation that would increase the risk of intramuscular injections or treatment\n             with Coumadin derivatives or heparin.\n\n          -  Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza\n             vaccine.\n\n          -  History of severe or previous serious adverse reaction after an influenza\n             vaccination.\n\n          -  Receipt of any immunoglobulin and/or blood products within 3 months of immunization\n             or planned administration of any of these products during the study period.\n\n          -  Prior history of any demyelinating disease including Guillain-Barre syndrome.\n\n          -  Presence of an active neurological disorder.\n\n          -  History of significant alcohol or drug abuse within one year prior to study\n             enrollment.\n\n          -  Influenza vaccination or laboratory confirmed influenza infection within the previous\n             six months before study vaccination or planned influenza vaccination during the study\n             period.\n\n          -  Planned administration of any non-influenza vaccines 30 days prior to the study or\n             during the study period.\n\n          -  Pregnant or plans to become pregnant during the study period.\n\n          -  Currently enrolled in another vaccine or drug study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1252", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688921", 
            "org_study_id": "PJ-501-12-2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "STRATIS", 
                    "Needle-Syringe"
                ], 
                "description": "Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.", 
                "intervention_name": "AFLURIA vaccine (2012-2013 formulation)", 
                "intervention_type": "Biological", 
                "other_name": [
                    "trivalent inactivated influenza vaccine (TIV)", 
                    "influenza virus vaccine"
                ]
            }, 
            {
                "arm_group_label": "Needle-Syringe", 
                "intervention_name": "Needle-Syringe", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "STRATIS", 
                "intervention_name": "STRATIS needle-free injection device", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Injections, Jet", 
            "Influenza Vaccines"
        ], 
        "lastchanged_date": "March 14, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ft. Collins", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80524"
                    }, 
                    "name": "Poudre Valley Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Collins", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80528"
                    }, 
                    "name": "University of Colorado Health Harmony Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Loveland", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80538"
                    }, 
                    "name": "Medical Center of the Rockies"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine", 
        "overall_official": [
            {
                "affiliation": "Rocky Mountain Infectious Disease Consultants", 
                "last_name": "David K Cobb, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "PharmaJet, Inc.", 
                "last_name": "Linda McAllister, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Anti influenza type A/H1N1 Hemagglutination Inhibition (HAI) antibody Geometric Mean Titer (GMT)", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Anti influenza type A/H3N2 HAI antibody GMT", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Anti influenza type B HAI antibody GMT", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of \u22651:40.", 
                "measure": "Anti influenza type A/H1N1 seroconversion", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of \u22651:40.", 
                "measure": "Anti influenza type A/H3N2 seroconversion", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of \u22651:40.", 
                "measure": "Anti influenza type B seroconversion", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following possible immediate complaints will be solicited following the 30 minute safety observation period post-vaccination:  pain at injection site, tenderness at injection site, redness, induration/swelling (lump), bruising, itching where the injection is given. The data will be reported as \"immediate complaints\" and presumed to be related to the test article. Any other symptom experienced at 30 minutes is to be recorded as an adverse event.", 
                "measure": "Proportion of subjects with immediate complaints", 
                "safety_issue": "Yes", 
                "time_frame": "30 minutes"
            }, 
            {
                "description": "Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination.  The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.", 
                "measure": "Proportion of subjects with vaccine reactogenicity events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0, 1, 2, 3, 4, 5, and 6"
            }, 
            {
                "description": "Subjects will be asked to report any other symptoms experienced in addition to the solicited \"immediate\" and \"vaccine reactogenicity\" events.  Any other events reported will be tabulated as spontaneously reported adverse events.", 
                "measure": "Proportion of subjects with spontaneously reported adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "PharmaJet, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaJet, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}